Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Pipeline

Home

Montserrat

Amplia Therapeutics Limited

Amplia has today announced that patient recruitment for the third cohort is now complete.

Participants in the ACCENT trial receive a dose of AMP945 given in combination with standard-of-care chemotherapy, in the treatment of advanced pancreatic cancer. After 1 month of treatment, the trial’s Safety Committee will review the clinical data to determine next steps in the trial.

Amplia’s CEO and Managing Director Dr Chris Burns commented:

“This achievement reflects the enthusiasm and commitment of the clinical trial sites in Melbourne, Sydney and Brisbane which has allowed recruitment for this cohort to be completed within one month of opening enrolment. As always, we thank the patients for consenting to be part of the trial.”

Enrolment of Cohort 3 of ACCENT Trial in Pancreatic Cancer Complete